Voyager Therapeutics Inc
VYGR3.245USD
+0.285+9.63%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
179.15MCap. mercado
PérdidaP/E TTM
Más Datos de Voyager Therapeutics Inc Compañía
Voyager Therapeutics, Inc. is a biotechnology company focused on advancing neurogenetic medicines. The Company’s pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of its programs are derived from its TRACER AAV capsid discovery platform, which is used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs, all of which are in preclinical development, include Anti-Tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy Program, Tau Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program, and others. VY-TAU01 is for the treatment of Alzheimer’s disease. SOD1 Silencing Gene Therapy Program is for the treatment of ALS.
Información de la empresa
Símbolo de cotizaciónVYGR
Nombre de la empresaVoyager Therapeutics Inc
Fecha de salida a bolsaNov 11, 2015
Director ejecutivoDr. Alfred W. Sandrock, M.D., Ph.D.
Número de empleados172
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 11
Dirección75 Hayden Avenue
CiudadLEXINGTON
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02421
Teléfono18572595340
Sitio Webhttps://www.voyagertherapeutics.com/
Símbolo de cotizaciónVYGR
Fecha de salida a bolsaNov 11, 2015
Director ejecutivoDr. Alfred W. Sandrock, M.D., Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Alfred W. Sandrock, M.D., Ph.D.
Dr. Alfred W. Sandrock, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
134.26K
-25.20%
Ms. Robin Swartz
Ms. Robin Swartz
Chief Operating Officer, Chief Business Officer
Chief Operating Officer, Chief Business Officer
84.49K
+250.80%
Dr. Toby Ferguson, M.D., Ph.D.
Dr. Toby Ferguson, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
24.91K
-85.17%
Dr. Glenn F. Pierce, M.D., Ph.D.
Dr. Glenn F. Pierce, M.D., Ph.D.
Independent Director
Independent Director
21.79K
--
Dr. Jude Onyia, Ph.D.
Dr. Jude Onyia, Ph.D.
Director
Director
2.91K
--
Dr. George A. Scangos, Ph.D.
Dr. George A. Scangos, Ph.D.
Independent Director
Independent Director
--
--
Dr. Catherine J. Mackey, Ph.D.
Dr. Catherine J. Mackey, Ph.D.
Independent Director
Independent Director
--
--
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Todd Carter, Ph.D.
Dr. Todd Carter, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. James Arthur (Jim) Geraghty, J.D.
Mr. James Arthur (Jim) Geraghty, J.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Alfred W. Sandrock, M.D., Ph.D.
Dr. Alfred W. Sandrock, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
134.26K
-25.20%
Ms. Robin Swartz
Ms. Robin Swartz
Chief Operating Officer, Chief Business Officer
Chief Operating Officer, Chief Business Officer
84.49K
+250.80%
Dr. Toby Ferguson, M.D., Ph.D.
Dr. Toby Ferguson, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
24.91K
-85.17%
Dr. Glenn F. Pierce, M.D., Ph.D.
Dr. Glenn F. Pierce, M.D., Ph.D.
Independent Director
Independent Director
21.79K
--
Dr. Jude Onyia, Ph.D.
Dr. Jude Onyia, Ph.D.
Director
Director
2.91K
--
Dr. George A. Scangos, Ph.D.
Dr. George A. Scangos, Ph.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Neurocrine Biosciences Inc
15.50%
Armistice Capital LLC
9.82%
EcoR1 Capital, LLC
7.08%
BlackRock Institutional Trust Company, N.A.
6.58%
The Vanguard Group, Inc.
5.80%
Other
55.22%
Accionistas
Accionistas
Proporción
Neurocrine Biosciences Inc
15.50%
Armistice Capital LLC
9.82%
EcoR1 Capital, LLC
7.08%
BlackRock Institutional Trust Company, N.A.
6.58%
The Vanguard Group, Inc.
5.80%
Other
55.22%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
23.35%
Investment Advisor
20.26%
Hedge Fund
16.83%
Corporation
15.50%
Research Firm
2.35%
Individual Investor
1.32%
Bank and Trust
0.57%
Pension Fund
0.50%
Venture Capital
0.03%
Other
19.30%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
301
44.67M
80.73%
-3.34M
2025Q1
320
44.96M
81.54%
-6.59M
2024Q4
316
44.59M
81.64%
-6.62M
2024Q3
302
45.03M
82.56%
-8.55M
2024Q2
298
47.92M
88.05%
-2.79M
2024Q1
277
45.43M
90.18%
+7.85M
2023Q4
257
36.58M
85.81%
-1.09M
2023Q3
248
36.63M
86.15%
-1.09M
2023Q2
242
36.26M
85.84%
+5.02M
2023Q1
252
33.40M
79.73%
+1.16M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Neurocrine Biosciences Inc
8.58M
15.5%
--
--
Apr 07, 2025
Armistice Capital LLC
5.44M
9.82%
+40.00K
+0.74%
Mar 31, 2025
EcoR1 Capital, LLC
3.92M
7.08%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.64M
6.58%
+9.42K
+0.26%
Mar 31, 2025
The Vanguard Group, Inc.
3.21M
5.8%
-4.36K
-0.14%
Mar 31, 2025
Farallon Capital Management, L.L.C.
2.57M
4.65%
--
--
Mar 31, 2025
Dimensional Fund Advisors, L.P.
1.50M
2.7%
+115.67K
+8.38%
Mar 31, 2025
BlackRock Financial Management, Inc.
1.43M
2.58%
+56.45K
+4.12%
Mar 31, 2025
Vestal Point Capital, LP
1.25M
2.26%
+19.42K
+1.58%
Mar 31, 2025
Erste Asset Management GmbH
1.12M
2.02%
+58.41K
+5.52%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Invesco NASDAQ Future Gen 200 ETF
0.51%
Tema Neuroscience and Mental Health ETF
0.42%
iShares Neuroscience and Healthcare ETF
0.34%
iShares Health Innovation Active ETF
0.06%
WisdomTree US SmallCap Fund
0.03%
WisdomTree US SmallCap Quality Growth Fund
0.03%
iShares Micro-Cap ETF
0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
Ver más
Invesco NASDAQ Future Gen 200 ETF
Proporción0.51%
Tema Neuroscience and Mental Health ETF
Proporción0.42%
iShares Neuroscience and Healthcare ETF
Proporción0.34%
iShares Health Innovation Active ETF
Proporción0.06%
WisdomTree US SmallCap Fund
Proporción0.03%
WisdomTree US SmallCap Quality Growth Fund
Proporción0.03%
iShares Micro-Cap ETF
Proporción0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporción0.02%
Invesco Nasdaq Biotechnology ETF
Proporción0.02%
ProShares Ultra Nasdaq Biotechnology
Proporción0.02%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
